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Abstract
Background: Reperfusion injury is an important limiting factor associated with revascularization 
in acute myocardial infarction (AMI). Various therapies have been tried in an attempt to prevent rep-
erfusion injury, but the search has been elusive. The role of cyclosporine A (CsA) in the prevention of 
reperfusion injury in AMI is still not clear. The objective of this study was to find out whether CsA is 
beneficial in reducing reperfusion injury in acute ST elevation myocardial infarction.
Methods: We performed a systematic search of Pubmed, Scopus, clinicaltrial.gov, and Cochrane Da-
tabase for randomized control trials (RCT) measuring the effect of CsA in AMI compared to a placebo. 
The Mantel-Haenszel method and random effect model were used to analyze the data. A total of 1,566 
patients (776 in the CsA group and 790 in the placebo group), who participated in 5 RCTs were included 
in our meta-analysis.
Results: We did not find any significant differences between the CsA and placebo groups in terms of 
all-cause death (odds ratio [OR] 1.21, 95% confidence interval [CI] 0.78–1.87) and cardiovascular 
death (OR 1.05, 95% CI 0.66–2.49). Similarly, we did not find any significant differences in terms of 
cardiogenic shock, recurrent ischemia and myocardial infarction, heart failure and echocardiographic 
outcomes.
Conclusions: Cyclosporine A is not helpful in preventing reperfusion injury in AMI. (Cardiol J 2017; 
24, 1: 43–50)
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Introduction
Although we have seen substantial advance-
ment in the field of coronary artery disease, mor-
tality rates still remain high. Reperfusion injury is 
an additional insult to already ischemic myocardial 
tissue. While percutaneous coronary intervention 
(PCI) attenuates the ischemic injury, it inadvert-
ently accentuates the reperfusion injury. The open-
ing of the mitochondrial permeability transition 
pore (MPTP) is one of the important mechanisms 
leading to reperfusion injury and cardio-myocyte 
death [1]. Since 1980s, cyclosporine A (CsA) has 
been known to inhibit opening of the MPTP [2]. 
Several experimental animal studies have been 
conducted to find the effects of CsA in reperfusion 
injury [3–17] and a meta-analysis, which included 
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CsA, showed reduced infarct size [18]. The first 
human study in acute ST elevation myocardial in-
farction (STEMI) using CsA was a small pilot study 
published in 2008 which showed reduced infarct 
size when compared to a placebo [19]. Studies 
published subsequently showed conflicting results 
[20]. We conducted this meta-analysis to find the 
protective effects of CsA in prevention of adverse 
clinical outcomes secondary to reperfusion injury.
Methods
The PRISMA statement for reporting meta-
analyses and systemic reviews, as recommended 
by the Cochrane Collaboration, was used for this 
meta-analysis (Fig. 1) [21]. Our search for studies 
published by 30th July 2016, was conducted through 
Pubmed, Cochrane library databases, clinicaltrial.
gov, and Scopus databases from inception. We used 
different strategies based on availability of Medical 
Subject Headings (MeSH) terms. For Pubmed and 
Cochrane library databases we used Mesh terms, 
“myocardial infarction” and “cyclosporine”, con-
nected with Boolean operator ‘AND’. For Scopus 
and clinicaltrial.gov we used following Boolean 
search strategy: (Myocardial infarction OR MI OR 
ACS OR STEMI) AND (Cyclosporine OR Cyclo-
sporins OR Cyclosporine A). Search strategies are 
elaborated on in Table 1. All results were reviewed. 
For our meta-analysis, we only used articles pub-
lished in English. We took all measures necessary 
to prevent data duplication and used only published 
data. Publication bias was not measured due to the 
small number of studies analyzed.
The eligibility criteria for this meta-anal-
ysis stated that each study must: 1) include 
human subjects undergoing any intervention 
for STEMI, either percutaneous intervention 
or thrombolysis; 2) a randomized control tri-
als (RCT) comparing pre-intervention CsA with 
a placebo; and 3) report relevant clinical or echocar-
diographic outcomes, whether primary or second-
ary. A total of 5 RCTs, which had been published 
in peer-reviewed journals, were included in our 
studies [19–24]. We extracted the baseline study 
details from all the selected trials (Tables 2, 3); 
outcomes not included in the analysis are listed 
in Table 4.
The clinical outcomes we measured were: 
all-cause death, cardiovascular death, heart fail-
Figure 1. PRISMA diagram for the review; CABG — coronary artery bypass grafting.
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ure, cardiogenic shock, recurrent ischemia and 
myocardial infarction, and major arrhythmias. We 
also measured echocardiographic outcomes: left 
ventricular ejection fraction (LVEF), left ven-
tricular end-systolic volume and left ventricular 
end-diastolic volume. All of the outcomes were 
calculated with RevMan, version 5.3, for Win-
dows (Cochrane Collaboration, Oxford, United 
Kingdom). Using random model, odds ratios (OR) 
were calculated with a confidence interval (CI) of 
95% and heterogeneity was calculated with I2. 
Mean difference and random model were used to 
analyze continuous data. A p-value of < 0.5 was 
considered significant.
Table 1. Search strategies for different databases.
Databases Search strategy 
Pubmed (Cyclosporines [MeSH Terms]) AND (Myocardial infarction [MeSH Terms]) 
SCOPUS TITLE-ABS-KEY (myocardial infarction OR ACS OR STEMI OR MI) AND TITLE-ABS-KEY  
(Cyclosporine a OR Cyclosporine OR Cyclosporines) 
Clinicaltrials.gov (myocardial infarction OR MI OR ACS OR STEMI) AND (Cyclosporine OR Cyclosporines OR 
Cyclosporine a)
Cochrane library Mesh descriptor [Cyclosporines] AND Mesh descriptor [Myocardial Infarction]
Table 2. Baseline characteristics of the patients. Data are given in Cyclosporine group/Control group 
format.
Ottani et al. 2016,  
CIRCUS study
Cung et al. 2015, 
CYCLE study 
Piot et al.  
2008
Ghaffari et al. 
2013
Mewton et al. 
2010
Number 395/396 207/203 30/28 50/51 15/13
Age 61.2/59.7 62.5/63.2 57/57 64/60.3 60/63
Male 333/323 167/160 25/21 38/46 12/8
Body mass index 26.6/26.9 27.1/26.4 26/27 N/A 27/25
Smokers 152/180 84/81 17/16 16/19 8/7
Diabetes mellitus 54/48 27/31 4/4 16/19 4/3
Hypertension 152/153 114/113 15/13 21/22 4/4
Dyslipidemia 158/154 72/83 14/12 8/6 6/4
Table 3. In-hospital strategies. Data are given in Cyclosporine group/Control group format.
Ottani et al. 2016, 
CIRCUS study
Cung et al. 2015, 
CYCLE study 
Piot et al. 
2008
Ghaffari et al. 
2013
Mewton et al. 
2010
Aspirin 371/363 205/202 29/24 49/51 15/13
Heparin 320/327 175/171 30/28 48/51 16/11
GP IIb/IIIa antagonist 155/154 90/92 11/10 Not available 4/5
Beta-blocker 424/455 164/167 Not available 46/45 13/11
ACEI/ARBs 405/427 147/146 Not available 49/51 13/10
Anterior infarct All anterior infarct 102/101 13/11 All anterior infarct 7/5
Primary intervention PCI PCI PCI Thrombolysis PCI
Initial TIMI flow < 2 345/361 207/203 3/1 Not applicable 2/1
TIMI flow after PCI  
or thrombolysis
2.68/2.86 2.82/2.88 2.7/2.7 2.63/2.78 2.7/2.8
Stent implanted 323/338 198/195 30/28 NA 16/11
ACEI/ARBs — angiotensin converting enzyme inhibitor/angiotensin receptor blockers; GP — glycoprotein; PCI — percutaneous intervention; 
TIMI — Thrombolysis In Myocardial Infarction
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Results
A total of 1,566 patients were included in our 
analysis, with 776 in the group which received CsA 
and 790 in the placebo group. We found no signifi-
cant differences between the two groups in terms 
of LVEF (mean difference 1.21, 95% CI –0.65–3.07) 
and left ventricular end-systolic volume (mean 
difference 1.60, 95% CI –4.01–7.22). Similarly, 
we did not find any significant differences in left 
ventricular end-diastolic volume (mean difference 
3.32, 95% CI –3.51–10.15) (Fig. 2). With regards 
to clinical outcomes, no significant differences in 
major arrhythmias (OR 0.84, 95% CI 0.60–1.18) or 
recurrent ischemia and myocardial infarction (OR 
0.72, 95% CI 0.34–1.53) (Fig. 2) were found. Ad-
ditionally, we did not find any significant differences 
when looking at all-cause death (OR 1.21, 95% CI 
0.78–1.87), cardiogenic shock (OR 1.23, 95% CI 
0.73–2.09), cardiovascular death (OR 1.05, 95% 
CI 0.66–2.49), and heart failure (OR 0.86, 95% CI 
0.55–1.35) (Fig. 3).
Discussion
The goal of our study was to find out whether 
the use of cyclosporine before reperfusion is as-
sociated with better clinical and echocardiographic 
outcomes or not. We did not find any significant 
differences between the two groups in terms of 
clinical and echocardiographic outcomes. The 
first proof-of-concept study of CsA (Sandimmune 
preparation) showed a significant difference in the 
release of creatine kinase when comparing the CsA 
group to the placebo group [19]. It was thought to 
bring paradigm shift in the prevention of reperfu-
sion injury. Subsequently, a larger RCT (CIRCUS 
study) was done, however, it failed to show any 
benefits in terms of primary outcome (adverse 
left ventricular remodeling, all-cause mortality 
and hospitalization for heart failure) (OR 1.04, 
95% CI 0.78–1.39) [22]. As hypothesized by the 
authors, this was likely due to the use of a different 
formulation of CsA; the CIRCUS study used the 
CicloMulsion formulation instead of the Sandim-
Table 4. Outcomes measured in the included studies, not measured in meta-analysis.
Outcome — median (IQR)  
or mean ± SD
Cyclosporine Control P
Cung et al., 2015
CIRCLE study
ST segment resolution* 52% 49% 0.55
High sensitivity cardiac TnT [ng/L] 2160 (1087–3274) 2068 (1117–3690) 0.85
LV wall motion score 1.35 ± 0.35 1.34 ± 0.34 0.78
LV akinetic/dyskinetic segments [%] 11.8 ± 14.4 12.6 ± 14 0.59
Ottani et al., 2016
CIRCUS study
ST elevation post PCI [mm] 2.7 ± 1.9 2.7 ± 1.9 NS
Peak CK [IU/L] 3992 (1910–5447) 3917 (1878–5608) NS
Adverse LV remodeling‡ 42.8% 40.7% 0.53














Mass of infarcted tissue  
on MRI on day 5 [g]
37 (21–51) 46 (20–65) 0.04
Mewton et al.,  
2010
Infarct size at 6 month [g] 29 ± 15 38 ± 14 0.04
Ghaffari et al.,  
2013
Peak CK-MB [IU/L] 271.8 ± 210.1 281.7 ± 208.3 0.81
Peak-TnI [ng/mL] 17.7 ± 11.2 18.1 ± 11.7 0.86
% ST segment resolution  
at 90 min [min]†
34.8 ± 6.4 36 ± 11.2 0.51
*≥ 70% resolution of ST segment elevation at 1 h after PCI.
‡An increase of 15% or more in the left ventricular end-diastolic volume.
†The reduction of the highest ST-segment elevation in any lead by at least 50% of the initial value in the first 60–90 min of treatment.
CK-MB — creatine kinase MB fraction, IQR — interquartile range; LV — left ventricle; MRI — magnetic resonance imaging; NS — not signifi-
cant; PCI — percutaneous coronary intervention; SD — standard deviation; TnI — troponin I, TnT — troponin T
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mune formulation. However, the recently pub-
lished CYCLE study, which used the Sandimmune 
formulation, failed to show a significant difference 
in primary endpoint (resolution of ST-segment 
≥ 70%) [20]. The CicloMulsion preparation has been 
 found to have similar pharmacokinetics and rather 
fewer adverse effects compared to Sandimmune 
preparation [25].
A study done on patients undergoing coronary 
artery bypass grafting surgery found no significant 
difference between the peak troponin T in CsA and 
placebo groups, except for the high-risk group with 
prolonged surgery — it showed that the extent of 
perioperative myocardial infarction was reduced 
in high-risk CsA patients [26]. Another RCT done 
in patients undergoing surgery for aortic stenosis 
showed a significant difference in the area under 
the curves for troponin I that favored the CsA group 
[27]. A few studies included in our meta-analysis 
used ST segment resolution as a surrogate marker 
of the successful coronary intervention [20, 23]. It 
has been proven in multiple studies that early and 
complete ST segment resolution is associated with 
better outcomes [28].
Figure 2. Forest plots of cyclosporine A versus placebo; A. Left ventricular ejection fraction; B. Left ventricular end-
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Figure 3. Forest plots of cyclosporine A versus placebo; A. All-cause death; B. Cardiogenic shock; C. Cardiovascular 
death; D. Heart failure.
Only the CYCLE study reported any adverse 
reactions to CsA. It reported a total of 5 adverse 
events, including one serious adverse drug reac-
tion [20]. In all studies, CsA was given in a single 
injection just before the intervention. All human 
studies used a dose of 2.5 mg/kg.
Several small pre-clinical studies have used 
CsA in animal models with mechanically occluded 
coronary arteries. There is extensive pre-clinical 
evidence that use of CsA during myocardial perfu-
sion reduces myocardial infarct size by up to 50% 
[29, 30]. This evidence not only regenerated the 
interest in reperfusion injury, but also leads to an 
increased understanding of the MPTP and Rep-
erfusion Injury Salvage Kinase (RISK) pathway. 
In disagreement with animal studies, most of the 
clinical studies failed to show any benefit to using 
CsA in STEMI patients.
The failure of this translation is likely due in 
part to the poor methodology of the pre-clinical 
studies. No best practice standards exist for animal 
trials, which tend to lack statistical robustness. 
Most of the animal studies had a very small sample 
size. Furthermore, only a few studies calculated 
the sample size [6, 31] and most did not disclose 
conflicts of interests [18]. Additionally, while most 
of the studies were done in rodents [18], the ma-
jority of those done in pigs showed cyclosporine 
fail to decrease infarct size [3, 31]. This striking 
difference between two animal species indicates 
the existence of variation in the mechanism of 
reperfusion injury between species. This concern 
appears more compelling in light of evidence from 
experiments showing that pigs, unlike rodents, do 
not need RISK pathway activation for protection 
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Another important root cause of failed trans-
lation is the inability of animal models to mimic 
the human pathology. Unlike animals, the human 
subjects in most trials had numerous comorbidities. 
The humans also were taking different medications 
which might interfere with reperfusion. Addition-
ally, disease models in animal studies are created by 
mechanical occlusion of relatively healthy coronary 
arteries. Human subjects, however, have thrombus 
formation secondary to plaque rupture in athero-
sclerotic coronary arteries.
Finally, cyclosporine has unique pharmaco-
dynamic and pharmacokinetic properties. Cyclo-
sporine is mainly metabolized by cytochrome P450 
3A4 (CYP3A4). There are more than 20 genetic 
polymorphisms of the CYP3A4 gene [34]. Major-
ity of these polymorphisms leads to decrease in 
function of the CYP3A4. Some of these polymor-
phisms are expressed by up to 9% of Caucasians 
[34]. Moving to pharmacokinetics, experiments 
have shown that CsA protects against reperfusion 
injury at a concentration between 0.4 and 2 µmol/L 
[35]. However, this protective effect is lost when 
the concentration exceeds 5 µmol/L.
Several studies have shown 2.5 mg/kg to 
be the optimal dose for the best protection 
against reperfusion injury [36]. Contrary to this 
evidence, dose-dependent pro-apoptotic effects 
have been observed with cyclosporine in many 
pre-clinical studies [37]. With these consid-
erations in mind, we believe that CsA-mediated 
protection is highly dose dependent and has 
a very narrow therapeutic index.
A recently published meta-analysis analyzed 
the effects of cyclosporine on the prevention of 
reperfusion injury in patients undergoing cardiac 
surgeries, PCI, and thrombolysis. It studied the 
effect on LVEF, creatine kinase-MB, and infarct 
size [38]. However, the authors did not report ad-
verse events and mortality data. It included three 
of the RCTs included in our analysis, along with 
one RCT in patient undergoing coronary artery 
bypass surgery and one RCT in patient undergo-
ing surgery for aortic stenosis [19, 23, 24, 26, 27]. 
Additionally, two of the larger trials comparing the 
effect of cyclosporine in acute myocardial infarction 
have been published recently and were not included 
in this study. This meta-analysis concluded that 
cyclosporine may not protect against reperfusion 
injury in clinical patients. The result of this meta-
analysis is in concordance with our conclusion.
Conclusions
Cyclosporine A use prior to percutaneous 
intervention or thrombolysis failed to show any 
significant decrease in the clinical and echocardio-
graphic outcomes in STEMI patients. It is time to 
explore new targets or other novel approaches to 
reduce reperfusion injury.
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